Information Provided By:
Fly News Breaks for June 6, 2016
OMED
Jun 6, 2016 | 12:46 EDT
Piper Jaffray analyst Edward Tenthoff noted that OncoMed presented new Phase Ib data from vantictumab and ipafricept at the ASCO meeting, adding that he was "particularly impressed" by early ipafricept signal in ovarian cancer. The analyst, who contends that OncoMed has a "rich pipeline" of seven cancer biotherapeutics in the clinic, keeps an Overweight rating and $29 price target on the stock.
News For OMED From the Last 2 Days
There are no results for your query OMED